<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We treated 109 patients with adult <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) diagnosed by histochemical and immunologic techniques </plain></SENT>
<SENT sid="1" pm="."><plain>Patients were excluded only for age greater than 50 years and Burkitt's <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment included a four-drug remission induction phase followed by alternating cycles of noncrossresistant chemotherapy and prolonged oral maintenance therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Eighty-eight percent of patients entered complete remission </plain></SENT>
<SENT sid="4" pm="."><plain>With a median follow-up of 77 months (range, 48 to 111 months), 42% +/- 6% (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SEM</z:e>) of patients achieving remission are projected to remain disease-free at 5 years, and disease-free survival for <z:hpo ids='HP_0000001'>all</z:hpo> patients entered on study is 35% +/- 5% </plain></SENT>
<SENT sid="5" pm="."><plain>Failure to achieve remission within the first 4 weeks of therapy and the presence of the Philadelphia chromosome are associated with a 100% risk of relapse </plain></SENT>
<SENT sid="6" pm="."><plain>Remission patients with neither of these adverse features have a 48% +/- 6% probability of remaining in continuous remission for 5 years </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with T-<z:mp ids='MP_0005384'>cell phenotype</z:mp> have a favorable prognosis with 59% +/- 13% of patients achieving remission remaining disease-free compared with 31% +/- 7% of CALLA-positive patients </plain></SENT>
<SENT sid="8" pm="."><plain>Intensive chemotherapy may produce prolonged disease-free survival in a sizable fraction of adults with ALL </plain></SENT>
<SENT sid="9" pm="."><plain>Improved therapy is needed, especially for patients with adverse prognostic features </plain></SENT>
</text></document>